GeneMedicine Co., Ltd.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
GeneMedicine is a gene therapeutic specializing bioventure with oncolytic adenovirus platform technologies.

[GM101]
Indication : Solid Tumor
Development stage : Preparing phase II clinical trial
GM oncolytic virus harboring state-of-the-art genetic modifications to maximize cancer-specific viral replication and killing effect.

[GM102]
Indication : Pancreatic cancer Development stage : Preparing phase I clinical trial
GM oncolytic virus that is capable of overcoming various challenges of the tumor microenvironment as well as optimizing viral replication in hypoxic solid tumors.

[GM103]
Indication : Metastatic liver and lung cancer
Development stage : Preparing phase I clinical trial
Highly tumor-specific GM oncolytic virus that is capable of inducing a strong antitumor immune response and antiangiogenic effect

[Platform Technology]
Indication : Metastatic or recurrent cancer
Development stage : Preparing phase I clinical trial
Systemically administrable GM oncolyt
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
GM 101, GM 102, GM 103
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Business Development
GeneMedicine Co., Ltd.